| Dr Christopher Michael Carter, MD | |
|
601 W 2nd St Rm 216, Bloomington, IN 47403 | |
| (812) 353-9533 | |
| Not Available |
| Full Name | Dr Christopher Michael Carter |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 21 Years |
| Location | 601 W 2nd St Rm 216, Bloomington, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639378250 | NPI | - | NPPES |
| 005944500 | Medicaid | FL |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Hospital | Vincennes, IN | Hospital |
| Indiana University Health Bloomington Hospital | Bloomington, IN | Hospital |
| Carle Richland Memorial Hospital | Olney, IL | Hospital |
| Indiana University Health | Indianapolis, IN | Hospital |
| Daviess Community Hospital | Washington, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Indiana University Health Bloomington Inc | 6709799851 | 3 |
| South Central Indiana Pathology, Pc | 7618037805 | 5 |
| Southern Indiana Pathologists | 5395776231 | 5 |
News Archive
GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced data which support the safety and efficacy of the EndoBarrier™ Gastrointestinal Liner for pre-surgical weight loss treatment, along with a positive effect on glucose homeostasis in morbidly obese patients with type 2 diabetes mellitus.
Coeliac disease cause by intolerance to gluten present in food and drinks like bread, pasta, cereals, biscuits and beer commonly affects many people all over the world. This affects 1 percent of all people in UK, especially women. Patients are advised to stay away from gluten to prevent damage to their intestines. In spite of this in five years most patients develop problems in their intestines. A gluten free diet is also difficult to maintain. Possible symptoms include diarrhoea, nausea and vomiting, recurrent stomach pain, tiredness, headaches, weight loss and mouth ulcers. These may be mild, moderate or severe in different individuals.
VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.
Hospital MRIs may be better at predicting long-term outcomes for people with mild traumatic brain injuries than CT scans, the standard technique for evaluating such injuries in the emergency room, according to a clinical trial led by researchers at the University of California, San Francisco (UCSF) and the San Francisco General Hospital and Trauma Center (SFGH).
The phosphate ion is almost insoluble and is one of the most inactive of Earth's most abundant phosphate minerals. So how could phosphate have originally been incorporated into ribonucleotides, the building blocks of RNA, which are considered to be among the earliest constituents of life? American and Spanish scientists have now identified reasonable conditions to mobilize phosphate from insoluble apatite minerals for prebiotic organophosphate synthesis, including ribonucleotides.
› Verified 6 days ago
| Entity Name | Indiana University Health Bloomington Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871519074 PECOS PAC ID: 6709799851 Enrollment ID: O20040305000288 |
News Archive
GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced data which support the safety and efficacy of the EndoBarrier™ Gastrointestinal Liner for pre-surgical weight loss treatment, along with a positive effect on glucose homeostasis in morbidly obese patients with type 2 diabetes mellitus.
Coeliac disease cause by intolerance to gluten present in food and drinks like bread, pasta, cereals, biscuits and beer commonly affects many people all over the world. This affects 1 percent of all people in UK, especially women. Patients are advised to stay away from gluten to prevent damage to their intestines. In spite of this in five years most patients develop problems in their intestines. A gluten free diet is also difficult to maintain. Possible symptoms include diarrhoea, nausea and vomiting, recurrent stomach pain, tiredness, headaches, weight loss and mouth ulcers. These may be mild, moderate or severe in different individuals.
VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.
Hospital MRIs may be better at predicting long-term outcomes for people with mild traumatic brain injuries than CT scans, the standard technique for evaluating such injuries in the emergency room, according to a clinical trial led by researchers at the University of California, San Francisco (UCSF) and the San Francisco General Hospital and Trauma Center (SFGH).
The phosphate ion is almost insoluble and is one of the most inactive of Earth's most abundant phosphate minerals. So how could phosphate have originally been incorporated into ribonucleotides, the building blocks of RNA, which are considered to be among the earliest constituents of life? American and Spanish scientists have now identified reasonable conditions to mobilize phosphate from insoluble apatite minerals for prebiotic organophosphate synthesis, including ribonucleotides.
› Verified 6 days ago
| Entity Name | Southern Indiana Pathologists |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447235619 PECOS PAC ID: 5395776231 Enrollment ID: O20050830000699 |
News Archive
GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced data which support the safety and efficacy of the EndoBarrier™ Gastrointestinal Liner for pre-surgical weight loss treatment, along with a positive effect on glucose homeostasis in morbidly obese patients with type 2 diabetes mellitus.
Coeliac disease cause by intolerance to gluten present in food and drinks like bread, pasta, cereals, biscuits and beer commonly affects many people all over the world. This affects 1 percent of all people in UK, especially women. Patients are advised to stay away from gluten to prevent damage to their intestines. In spite of this in five years most patients develop problems in their intestines. A gluten free diet is also difficult to maintain. Possible symptoms include diarrhoea, nausea and vomiting, recurrent stomach pain, tiredness, headaches, weight loss and mouth ulcers. These may be mild, moderate or severe in different individuals.
VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.
Hospital MRIs may be better at predicting long-term outcomes for people with mild traumatic brain injuries than CT scans, the standard technique for evaluating such injuries in the emergency room, according to a clinical trial led by researchers at the University of California, San Francisco (UCSF) and the San Francisco General Hospital and Trauma Center (SFGH).
The phosphate ion is almost insoluble and is one of the most inactive of Earth's most abundant phosphate minerals. So how could phosphate have originally been incorporated into ribonucleotides, the building blocks of RNA, which are considered to be among the earliest constituents of life? American and Spanish scientists have now identified reasonable conditions to mobilize phosphate from insoluble apatite minerals for prebiotic organophosphate synthesis, including ribonucleotides.
› Verified 6 days ago
| Entity Name | Good Samaritan Hospital Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649432071 PECOS PAC ID: 3971671330 Enrollment ID: O20081013000182 |
News Archive
GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced data which support the safety and efficacy of the EndoBarrier™ Gastrointestinal Liner for pre-surgical weight loss treatment, along with a positive effect on glucose homeostasis in morbidly obese patients with type 2 diabetes mellitus.
Coeliac disease cause by intolerance to gluten present in food and drinks like bread, pasta, cereals, biscuits and beer commonly affects many people all over the world. This affects 1 percent of all people in UK, especially women. Patients are advised to stay away from gluten to prevent damage to their intestines. In spite of this in five years most patients develop problems in their intestines. A gluten free diet is also difficult to maintain. Possible symptoms include diarrhoea, nausea and vomiting, recurrent stomach pain, tiredness, headaches, weight loss and mouth ulcers. These may be mild, moderate or severe in different individuals.
VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.
Hospital MRIs may be better at predicting long-term outcomes for people with mild traumatic brain injuries than CT scans, the standard technique for evaluating such injuries in the emergency room, according to a clinical trial led by researchers at the University of California, San Francisco (UCSF) and the San Francisco General Hospital and Trauma Center (SFGH).
The phosphate ion is almost insoluble and is one of the most inactive of Earth's most abundant phosphate minerals. So how could phosphate have originally been incorporated into ribonucleotides, the building blocks of RNA, which are considered to be among the earliest constituents of life? American and Spanish scientists have now identified reasonable conditions to mobilize phosphate from insoluble apatite minerals for prebiotic organophosphate synthesis, including ribonucleotides.
› Verified 6 days ago
| Entity Name | South Central Indiana Pathology, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194813154 PECOS PAC ID: 7618037805 Enrollment ID: O20090205000101 |
News Archive
GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced data which support the safety and efficacy of the EndoBarrier™ Gastrointestinal Liner for pre-surgical weight loss treatment, along with a positive effect on glucose homeostasis in morbidly obese patients with type 2 diabetes mellitus.
Coeliac disease cause by intolerance to gluten present in food and drinks like bread, pasta, cereals, biscuits and beer commonly affects many people all over the world. This affects 1 percent of all people in UK, especially women. Patients are advised to stay away from gluten to prevent damage to their intestines. In spite of this in five years most patients develop problems in their intestines. A gluten free diet is also difficult to maintain. Possible symptoms include diarrhoea, nausea and vomiting, recurrent stomach pain, tiredness, headaches, weight loss and mouth ulcers. These may be mild, moderate or severe in different individuals.
VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.
Hospital MRIs may be better at predicting long-term outcomes for people with mild traumatic brain injuries than CT scans, the standard technique for evaluating such injuries in the emergency room, according to a clinical trial led by researchers at the University of California, San Francisco (UCSF) and the San Francisco General Hospital and Trauma Center (SFGH).
The phosphate ion is almost insoluble and is one of the most inactive of Earth's most abundant phosphate minerals. So how could phosphate have originally been incorporated into ribonucleotides, the building blocks of RNA, which are considered to be among the earliest constituents of life? American and Spanish scientists have now identified reasonable conditions to mobilize phosphate from insoluble apatite minerals for prebiotic organophosphate synthesis, including ribonucleotides.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher Michael Carter, MD 601 W 2nd St Rm 216, Bloomington, IN 47403-2317 Ph: (812) 353-9533 | Dr Christopher Michael Carter, MD 601 W 2nd St Rm 216, Bloomington, IN 47403 Ph: (812) 353-9533 |
News Archive
GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced data which support the safety and efficacy of the EndoBarrier™ Gastrointestinal Liner for pre-surgical weight loss treatment, along with a positive effect on glucose homeostasis in morbidly obese patients with type 2 diabetes mellitus.
Coeliac disease cause by intolerance to gluten present in food and drinks like bread, pasta, cereals, biscuits and beer commonly affects many people all over the world. This affects 1 percent of all people in UK, especially women. Patients are advised to stay away from gluten to prevent damage to their intestines. In spite of this in five years most patients develop problems in their intestines. A gluten free diet is also difficult to maintain. Possible symptoms include diarrhoea, nausea and vomiting, recurrent stomach pain, tiredness, headaches, weight loss and mouth ulcers. These may be mild, moderate or severe in different individuals.
VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.
Hospital MRIs may be better at predicting long-term outcomes for people with mild traumatic brain injuries than CT scans, the standard technique for evaluating such injuries in the emergency room, according to a clinical trial led by researchers at the University of California, San Francisco (UCSF) and the San Francisco General Hospital and Trauma Center (SFGH).
The phosphate ion is almost insoluble and is one of the most inactive of Earth's most abundant phosphate minerals. So how could phosphate have originally been incorporated into ribonucleotides, the building blocks of RNA, which are considered to be among the earliest constituents of life? American and Spanish scientists have now identified reasonable conditions to mobilize phosphate from insoluble apatite minerals for prebiotic organophosphate synthesis, including ribonucleotides.
› Verified 6 days ago
Beatriz Sanchez, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 601 West Second Street, Bloomington, IN 47402 Phone: 812-336-6821 Fax: 419-866-5453 | |
Dr. James Alexander Isom, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2651 E Discovery Pkwy, Bloomington, IN 47408 Phone: 812-918-3336 Fax: 812-918-5887 | |
Dr. Robert D Lodge-rigal, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 601 West Second Street, Bloomington, IN 47402 Phone: 812-336-6821 Fax: 419-866-5453 | |
Mark Braun, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1001 E 3rd St, Medical Sciences, Jordan Hall 104, Bloomington, IN 47405 Phone: 812-855-8118 Fax: 812-855-4436 | |
Dr. Marcia Jo Campbell, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 601 W 2nd St, Bloomington, IN 47403 Phone: 812-336-6821 | |
Dr. Mark E Bauman, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 601 W 2nd St, Bloomington, IN 47403 Phone: 812-336-6821 |